PMV Pharmaceuticals (NASDAQ:PMVP) Given “Sell (D-)” Rating at Weiss Ratings

Weiss Ratings restated their sell (d-) rating on shares of PMV Pharmaceuticals (NASDAQ:PMVP) in a report issued on Tuesday morning,Weiss Ratings reports.

PMV Pharmaceuticals Stock Up 7.6%

NASDAQ PMVP opened at $1.42 on Tuesday. PMV Pharmaceuticals has a 52-week low of $0.81 and a 52-week high of $1.84. The business’s 50-day moving average price is $1.41 and its 200 day moving average price is $1.19. The firm has a market cap of $75.25 million, a P/E ratio of -0.90 and a beta of 1.51.

PMV Pharmaceuticals (NASDAQ:PMVP) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). As a group, analysts anticipate that PMV Pharmaceuticals will post -1.06 earnings per share for the current year.

Insiders Place Their Bets

In other PMV Pharmaceuticals news, major shareholder Orbimed Advisors Llc sold 500,000 shares of PMV Pharmaceuticals stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $1.80, for a total value of $900,000.00. Following the sale, the insider owned 5,975,291 shares of the company’s stock, valued at approximately $10,755,523.80. The trade was a 7.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On PMV Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC boosted its holdings in PMV Pharmaceuticals by 0.9% in the 2nd quarter. Acadian Asset Management LLC now owns 2,066,137 shares of the company’s stock valued at $2,188,000 after purchasing an additional 18,960 shares in the last quarter. Aldebaran Capital LLC boosted its holdings in PMV Pharmaceuticals by 4.3% in the 1st quarter. Aldebaran Capital LLC now owns 523,553 shares of the company’s stock valued at $571,000 after purchasing an additional 21,363 shares in the last quarter. Shay Capital LLC purchased a new stake in PMV Pharmaceuticals in the 2nd quarter valued at approximately $26,000. Peapod Lane Capital LLC lifted its position in shares of PMV Pharmaceuticals by 9.8% during the 1st quarter. Peapod Lane Capital LLC now owns 489,370 shares of the company’s stock valued at $533,000 after acquiring an additional 43,626 shares during the period. Finally, Stonepine Capital Management LLC lifted its position in shares of PMV Pharmaceuticals by 17.6% during the 1st quarter. Stonepine Capital Management LLC now owns 630,183 shares of the company’s stock valued at $687,000 after acquiring an additional 94,378 shares during the period. Hedge funds and other institutional investors own 90.20% of the company’s stock.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.